WP1066 induces cell death in a schwannomatosis patient–derived schwannoma cell line
Open Access
- 22 June 2022
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 8 (4), a006178
- https://doi.org/10.1101/mcs.a006178
Abstract
Schwannomatosis is a rare genetic disorder that predisposes individuals to development of multiple schwannomas mainly in spinal and peripheral nerves and to debilitating chronic pain often unrelated to any schwannoma. Pathogenic variants of two genes, SMARCB1 and LZTR1, are causal in familial cases. However, many schwannomatosis patients lack mutations in these genes. Surgery is the standard treatment for schwannomas but leaves patients with increasing neurological deficits. Pain management is a daily struggle controlled by the use of multiple analgesic and anti-inflammatory drugs. There is a need for both nonsurgical treatment to manage tumor growth and nonaddictive, nonsedative pain control. Because standard clinical trials are exceedingly difficult for patients with rare disorders, precision medicine approaches offer the possibility of bespoke therapeutic regimens to control tumor growth. As a proof of principle, we obtained a bio-specimen of paraspinal schwannoma from a schwannomatosis patient with a germline point mutation in the SMARCB1/INI gene. We created an hTERT immortalized cell line and tested the ability of targeted small molecules with efficacy in neurofibromatosis type 2–related schwannomas to reduce cell viability and induce cell death. We identified WP1066, a STAT3 inhibitor, currently in phase 2 clinical trials for pediatric and adult brain tumors as a lead compound. It reduced cell viability and STAT-3 phosphorylation and induced expression of markers for both necroptosis and caspase-dependent cell death. The results demonstrate feasibility in creating patient-derived cell lines for use in precision medicine studies.Keywords
This publication has 38 references indexed in Scilit:
- Frequency of SMARCB1 mutations in familial and sporadic schwannomatosisneurogenetics, 2012
- Regulation of Src Family Kinases in Human CancersJournal of Signal Transduction, 2011
- A novel imaging-compatible sciatic nerve schwannoma modelJournal of Neuroscience Methods, 2011
- The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignanciesSurgical Neurology International, 2011
- A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cellsCancer Immunology, Immunotherapy, 2008
- A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T CellsClinical Cancer Research, 2008
- Evidence of a four-hit mechanism involvingSMARCB1andNF2in schwannomatosis-associated schwannomasHuman Mutation, 2007
- A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma PatientsCancer Research, 2007
- Serum and forskolin cooperate to promote G1 progression in Schwann cells by differentially regulating cyclin D1, cyclin E1, and p27Kip expressionGlia, 2007
- Comparison of human mammary epithelial cells immortalized by simian virus 40 T-Antigen or by the telomerase catalytic subunitOncogene, 2002